Viracta Therapeutics’ (VIRX) Neutral Rating Reaffirmed at Rodman & Renshaw

Posted by Scott Moore on Dec 30th, 2024

Rodman & Renshaw reiterated their neutral rating on shares of Viracta Therapeutics (NASDAQ:VIRX – Free Report) in a research report released on Friday,Benzinga reports. The brokerage currently has a $0.25 price objective on the stock, down from their previous price objective of $3.50.

Separately, Royal Bank of Canada dropped their price objective on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.05.

Check Out Our Latest Report on Viracta Therapeutics

Viracta Therapeutics Trading Down 32.5 %

Shares of VIRX stock opened at $0.16 on Friday. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31. The company has a market capitalization of $6.36 million, a P/E ratio of -0.15 and a beta of 0.67. The stock has a 50 day moving average of $0.19 and a two-hundred day moving average of $0.31.

Institutional Trading of Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC bought a new stake in Viracta Therapeutics, Inc. (NASDAQ:VIRX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Viracta Therapeutics

(Get Free Report)

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.